drugset / Trial / NCT01128530
Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the clinical efficacy, safety, and tolerability of a 250 mg BID oral dose of JNJ-32729463 compared with linezolid in subjects with complicated skin and skin structure infections (cSSSIs).
Timeline
- Start
- 2010-06
- Primary completion
- 2010-12
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACORAFLOXACIN | Small molecule | 250 mg | Oral |
| Comparator | Linezolid | Other / unclassified | 600 mg | — |
Indications
No indication recorded.